Document Detail


The US Approach to Biosimilars: The Long-Awaited FDA Approval Pathway.
MedLine Citation:
PMID:  23030677     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
In the US, the Biologics Price Competition and Innovation Act (BPCI Act, 2009) provided the pathway to create an abbreviated licensure procedure for biologic products that are demonstrated to be biosimilar to or interchangeable with a Food and Drug Administration (FDA) licensed biologic product. In February 2012, the FDA issued three guidelines that list the requirements for biosimilar registration. The topics covered include scientific and quality considerations to demonstrate biosimilarity to a reference product and a guidance that clarifies the BPCI Act implementation. The sponsor application for the biosimilar approval must contain biosimilarity information based on data derived from analytical, animal, and clinical studies. Clinical studies should include an assessment of immunogenicity, pharmacokinetics, pharmacodynamics, and address one or more indications licensed for the reference product. To demonstrate biosimilarity the applicant is allowed to use comparative animal or clinical data with a non-US-licensed product. According to these guidelines, the FDA will consider different aspects when evaluating biosimilarity, such as product formulation, complexity, and stability which will have a risk-based approach and will depend on the degree of knowledge of the product characteristics, as well as clinical experience with the reference one. The FDA intends to use a risk-based and facts-focused approach for review of applications of biosimilars, although it faces several challenges. Once a biologic medicine has been demonstrated to be biosimilar to the reference product, an abridged development program for the biosimilar medicine can be carried out in a similar way to that established by the European Medicines Agency (EMA). In addition, FDA legislation goes a step further than the EMA, offering the possibility to adopt full interchangeability for biosimilars.
Authors:
Begoña Calvo; Leyre Zuñiga
Related Documents :
9125967 - Goodbye to all that: centennial cycles in academic medicine.
12496507 - Think clearly, be sincere, act calmly: adolf kussmaul (february 22, 1822-may 28, 1902) ...
24872927 - Why is research on herbal medicinal products important and how can we improve its quality?
12537807 - An introduction to reproduction in pharaonic egypt.
1471837 - Audit of an oesophageal unit.
18433977 - The role of laparoscopy in the treatment of early ovarian carcinoma.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-3
Journal Detail:
Title:  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy     Volume:  -     ISSN:  1173-8804     ISO Abbreviation:  BioDrugs     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9705305     Medline TA:  BioDrugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Pharmaceutical Technology Department, Faculty of Pharmacy, University of the Basque Country, Vitoria-Gasteiz, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Causal Attributions of Cleft Lips and Palates Across Cultures.
Next Document:  Factors Associated with Differences in Canadian Perinatal Nurses' Attitudes Toward Birth Practices.